Charles River U.K. Limited
Registered name: CHARLES RIVER U.K. LIMITED
Charles River U.K. Limited made £22.2m revenue and £18.8m profit in the year to 27 Dec 2025.
Charles River U.K. Limited’s revenue fell 5% to £22.2m in the year to 27 Dec 2025, with £18.8m profit and 129 employees. The company is classified under “research and experimental development on biotechnology” and is based in Kent; we hold 3 years of its filed accounts.
- Status
- Active
- Location
- Kent, South East
- Age
- 57 yrs · since 1969
- Type
- Private Limited Company
Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently. From the filing: “Charles River Laboratories Holdings Limited”
Key figures
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 30 Dec 2023 | 28 Dec 2024 | 27 Dec 2025 |
|---|---|---|---|
| Disclosure | Full P&L | Full P&L | Full P&L |
| Profit & loss | |||
| Revenue (turnover) | £21.1m | £23.4m | £22.2m |
| Cost of sales | £12.8m | £14.2m | £13.8m |
| Gross profit | £8.3m | £9.3m | £8.3m |
| Operating profit | £1.8m | £991k | £1.7m |
| Profit before tax | £13m | £16.7m | £20.1m |
| Profit after tax | £12.4m | £15.3m | £18.8m |
| Profit (best available) | £12.4m | £15.3m | £18.8m |
| Staff costs | £6.2m | £6.7m | £7.7m |
| Employees (average) | 124 | 125 | 129 |
| Ratios | |||
| Profit margin | 58.8% | 65.4% | 84.9% |
| Gross margin | 39.3% | 39.5% | 37.6% |
| Revenue per employee | £170k | £187k | £172k |
| Profit per employee | £100k | £123k | £146k |
| Growth (year on year) | |||
| Revenue growth | — | ▲10.9% | ▼5.4% |
| Profit growth | — | ▲23.3% | ▲22.9% |
| Headcount growth | — | ▲0.8% | ▲3.2% |
| Balance sheet — indirect signals, not revenue | |||
| Cash at bank | £2m | £0 | — |
| Net assets | £77.3m | £90.5m | £108m |
| Fixed assets | £91.9m | £102m | £102m |
| Current assets | £7.4m | £8m | £10.5m |
| Debtors | £2.5m | £2.2m | £2.1m |
| Deferred income | £16.2m | £16.6m | £1.7m |
| Source | Full Accounts · bulk data Sep 2025 | Full Accounts · bulk data Sep 2025 | Full Accounts · bulk data Jun 2026 |
How the business works
- Profit margin
- 84.9%
- Profit ÷ revenue.
- Gross margin
- 37.6%
- Gross profit ÷ revenue. High for software and services.
- Revenue per employee
- £172k
- Revenue ÷ average employees.
- Profit per employee
- £146k
- Profit ÷ average employees.
- Cash conversion
- —
- Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
- Fixed assets ÷ revenue
- 460.7%
- Capital intensity. Low = capital-light, cheaper to start.
- Deferred income ÷ revenue
- 7.6%
- Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
- Debtors ÷ revenue
- 9.6%
- Money owed by customers. Low = customers pay quickly.
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- ▲20%
- Now £108m
- Cash at bank
- —
- Now —
- Headcount
- ▲3%
- Now 129
- Deferred income
- ▼90%
- Now £1.7m
- Fixed assets
- ▲0%
- Now £102m
Deferred income is reported together with accruals in this filing (“accruals and deferred income”), so it is an approximate signal only.
Group structure
Minority corporate shareholders
- Charles River Laboratories International Inc. (registered outside the UK register)
From the Persons with Significant Control register (corporate controllers only).
Similar profitable businesses
- Sitryx Therapeutics LimitedOxford · Research and experimental development on biotechnology
- Revenue
- £23.3m
- Profit
- £4.7m
- Staff
- —
- Origio LimitedFareham · Research and experimental development on biotechnology
- Revenue
- £20.1m
- Profit
- £499k
- Staff
- 82
- Enara Bio LimitedOxford · Research and experimental development on biotechnology
- Revenue
- £17.4m
- Profit
- £1.3m
- Staff
- 54
- Alchemab Therapeutics LtdLondon · Research and experimental development on biotechnology
- Revenue
- £30m
- Profit
- £8.3m
- Staff
- 55
- Theradex (Europe) LimitedRedhill · Research and experimental development on biotechnology
- Revenue
- £15.2m
- Profit
- £3.1m
- Staff
- 43
- Amphista Therapeutics LimitedCambridge · Research and experimental development on biotechnology
- Revenue
- £33.9m
- Profit
- £19.8m
- Staff
- 56
Sources
Latest figures from Full Accounts for the year to 27 Dec 2025 (profit £18.8m), from the Companies House accounts bulk data published Jun 2026. Spotted an error? Request a correction.
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.